

CLAIMS AMENDMENT

1-19. (canceled)

20. (currently amended): A method for enhanced magnetic resonance imaging of a target tissue in a subject *in vivo* which method comprises

detecting a magnetic resonance image of said target tissue wherein said target tissue is bound to a ligand specific for said target tissue and wherein said ligand is directly coupled to lipid-coated ~~liquid-perfluorocarbon~~ particles consisting of liquid perfluorocarbon, said coated particles contained in an emulsion,

which method further comprises, prior to said detecting, administering said emulsion to said subject.

21. (currently amended): The method of claim 20, wherein said lipid-coated ~~liquid perfluorocarbon~~ particles further comprise at least one chemotherapeutic agent or gene therapy delivery system.

22. (previously presented): The method of claim 20, wherein said ligand comprises an antibody or fragment thereof, a virus, a receptor agonist or antagonist, a hormone, or a nucleic acid.

23. (previously presented): The method of claim 22, wherein the ligand is an antibody or fragment thereof.

24. (currently amended): A method for enhanced magnetic resonance imaging of a target tissue in a subject *in vivo* which method comprises administering to said subject an emulsion comprising a ligand specific for said target tissue, said ligand directly coupled to lipid-coated ~~liquid-perfluorocarbon~~ particles consisting of liquid perfluorocarbon, and

detecting a magnetic resonance image of said target tissue wherein said target tissue is bound to said ligand and wherein said ligand is directly coupled to lipid-coated ~~liquid perfluorocarbon~~ particles contained in said emulsion.

25. (currently amended): The method of claim 24, wherein said lipid-coated ~~liquid perfluorocarbon~~ particles further comprise at least one chemotherapeutic agent or gene therapy delivery system.

26. (previously presented): The method of claim 24, wherein said ligand comprises an antibody or fragment thereof, a virus, a receptor agonist or antagonist, a hormone, or a nucleic acid.

27. (previously presented): The method of claim 26, wherein the ligand is an antibody or fragment thereof.

28. (currently amended): A method for magnetic resonance ~~ultrasound~~ imaging of a target tissue in a subject *in vivo* which method comprises

detecting a magnetic resonance image of said target tissue wherein said target tissue is bound to a ligand specific for said target tissue and wherein said ligand is directly coupled to lipid-coated ~~liquid perfluorocarbon~~ particles consisting of liquid perfluorocarbon, said coated particles contained in an emulsion,

wherein said subject has been administered said emulsion prior to said detecting.

29. (currently amended): The method of claim 28, wherein said lipid-coated ~~liquid perfluorocarbon~~ particles further comprise at least one chemotherapeutic agent or gene therapy delivery system.

30. (previously presented): The method of claim 28, wherein said ligand comprises an antibody or fragment thereof, a virus, a receptor agonist or antagonist, a hormone, or a nucleic acid.

31. (previously presented): The method of claim 30, wherein the ligand is an antibody or fragment thereof.